Antiangiogenesis drug

Case Study Discovery and Development of Antiangiogenesis Drugs ... 

In 2004, bevacizumab (Avastin) became the first antiangiogenesis drug to receive FDA approval. It is intended for combination use with standard chemotherapy for metastatic colon cancer. Approval for other indications as part of combination therapy followed non-small-cell lung cancer and breast cancer. The cost for bevacizumab s research and development was 2.25 billion. 

The author thanks Dr. John Holaday for his comments on the discovery and development of antiangiogenesis drugs. 

Zhong H, Bowen JP. Antiangiogenesis drug design multiple pathways targeting tumor vasculature. Curr Med Chem. 2006 13 849-862. 

The embolization is performed by arterial approach for types 1,2,3, and 5, and by transhepatic transvenous approach for portovenous shunts in type 4. Platinum fiber microcoils are generally safe in types 3,4 and 5, and permit the occlusion of the shunts. Glue (n-butyl-2-cyanoacrylate) is the most effective material in patients with direct arteriovenous and arterioportal shunting arising from multiple sources [21]. Medical antiangiogenesis drugs... 

Susman E. Consensus panel Antiangiogenesis drugs unlikely as single agents. Oncology Times June, 2001. 

---